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CorrespondenceThe Duffy Antigen Receptor for
Chemokines Null Promoter Variant
Does Not Influence HIV-1
Acquisition or Disease ProgressionWe read with great interest the article by
He et al. (2008) describing the effects on
HIV acquisition and disease progression
of a single-nucleotide polymorphism
(SNP) (rs2814778,46T/C) that disrupts
the promoter region of the Duffy antigen
receptor for chemokines (DARC) gene
and abolishes gene expression in red
blood cells. He et al. reported that
HIV-infected African Americans have a
frequency of the null homozygous geno-
type (46C/C) of 70%, while non-HIV-
infected individuals have a null genotype
frequency of 60%. Based on this fre-
quency difference, they argued that the
null allele confers susceptibility to infec-
tion with HIV-1. They also reported that
the null genotype is associatedwith better
outcomes among those who do become
infected, including longer survival, slower
loss of CD4+ T lymphocytes, and delayed
progression to HIV-associated dementia.
We sought to evaluate these suggested
associations using a cohort of 471 HIV-1-
infectedAfricanAmericanswith estimated
seroconversion dates enrolled in the Tri-
Service AIDS Clinical Consortium (TACC)
HIV Natural History Study (NHS) and 227
HIV-negative African Americans recruited
in conjunction with ongoing genetic
studies at Duke University in Durham, NC.
A principal component-based procedure
implemented in the EigenSoft routines
(Price et al., 2006) was used to correct
for population structure. This approach
has been extensively used to adjust for
population stratification that would other-
wise inflate association statistics (McCar-
thy et al., 2008).
In assessing population stratification
in the 698 African Americans using
EIGENSTRAT (Price et al., 2006), the first
axis makes a much larger contribution to
the proportion of variation explained than
other axes and reflects the degree of
African versus European ancestry in indi-
viduals (Figure1A). To further demonstrate
the separation of African and European
ancestries in the admixed African Amer-
ican population, we added 60 HapMap408 Cell Host & Microbe 5, May 21, 2009 ªUtah residents with ancestry from
northern and western Europe and 60
HapMap Yoruba in Ibadan, Nigeria
samples into the EIGENSTRAT analysis
(see Supplemental Data). The first axis
separates African and European ances-
tries and is highly correlated to the first
axis without the seed populations (r2 =
0.9958) (Supplemental Data). We note
that the DARC 46T/C polymorphism
is strongly associated with the first axis
(p = 6.14 3 1023) (Figure 1B). This
confirms that the DARC 46T/C poly-
morphism itself is highly informative about
ancestry in African American populations,
as expected, and that it could therefore
generate strong associations due to strat-
ification for any traits that correlate with
ancestry.
We tested for an effect of the DARC
46T/C polymorphism on viral load at
set-point, progression to AIDS, and CD4+
T cell decline. Viral set-point was defined
as previously described (Fellay et al.,
2007) for 394 HIV-infected patients. A
linear regression using gender, age at
seroconversion, and thefirstEIGENSTRAT
axis as covariates revealed no association
with theDARC46C/C genotype and viral
set-point (p = 0.524; when not corrected
for population stratification, p = 0.905).
We defined HIV disease progression as
time to AIDS (1993 CDC definition).
Because many subjects in the cohort
eventually initiated highly active antiretro-
viral therapy (HAART), we considered
multiplemethods to account for treatment
initiation in our statistical models. In our
primary model, subjects were censored
at HAART initiation so that time to AIDS
is considered only in untreated patients
to rule out any effects of HAART. The
Cox proportional hazards model was
adjusted for gender, age at seroconver-
sion, and the first EIGENSTRAT axis
and shows no association between the
46C/C genotype and faster disease
progression (hazard ratio [HR] 1.53, 95%
confidence interval [CI] 0.921–2.54, p =
0.101; without correction for population2009 Elsevier Inc.stratification, HR = 1.52, 95% CI 0.932–
2.47, p = 0.094) (see Supplemental Data
for Kaplan-Meier curves). Censoring at
January 1, 1996 (the approximate date
when HAART first became available to
thecohort) as opposed toHAART initiation
produced similar results (data not shown).
In a separate model adjusted for the same
covariates, we considered HAART as a
time-updated covariate rather than cen-
soring at HAART initiation. In this anal-
ysis, there was no significant association
between 46C/C genotype and disease
progression (HR 1.37, 95% CI 0.854–
2.21, p = 0.191; without correction for
population stratification, HR = 1.28, 95%
CI 0.835–1.97, p = 0.256) (see Supple-
mental Data for Kaplan-Meier curves).
Lastly,weconsidered anexpandeddefini-
tion of progression that also included as
progressors those patients who started
HAART with CD4+ T cell counts of
less than 350/mm3. The follow-up was
censored at HAART initiation for those
patients who started treatment with
CD4+ T cell counts greater than 350/mm3.
Single or dual treatment with nucleoside
reverse transcriptase inhibitors was in-
cluded in the analysis as a time-updated
covariate. This model again showed no
effect of the DARC 46C/C genotype on
disease progression (HR = 1.16, 95% CI
0.792–1.70, p = 0.446; without correction
for population stratification, HR = 1.13,
95% CI 0.797–1.60, p = 0.496) (see
Supplemental Data for Kaplan-Meier
curves).
The rate of CD4+ T cell decline prior
to HAART initiation was assessed as an
additional biological marker of disease
progression. CD4+ counts over time
were considered for all samples with > 3
pre-HAART CD4+ counts available. The
average rate of CD4+ decline in these
samples (n = 263) was 5.10 cells per
month.Forpatientswith the46C/Cgeno-
type, the rate of CD4+ decline was 5.32
cells per month, and for all other patients
it was 4.55 cells per month. Finally, an
analysis using a mixed linear model, which
included as covariates gender, age at
seroconversion, and thefirst EIGENSTRAT
axis, failed to demonstrate a significant
effect of genotype with respect to rate of
CD4+ T cell decline (p = 0.9359).
We also tested for an effect of 46C/C
genotype on risk of HIV acquisition. The
frequency of the 46C/C genotype was
not significantly different between the
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(A) The high eigenvalue for the first axis indicates that this axis accounts for a large proportion of population structure in our sample. This axis represents the
degree of African versus European chromosomal ancestry on a genome-wide level (see Supplemental Data for further information).
(B) The principal component (PC) score for each subject along axis one (PC1) is significantly correlated with genotype at rs2814778, highlighting the importance of
stratification control for association testing at this polymorphism.HIV-infected and non-HIV-infected Afri-
can Americans in this study (70.7% and
68.3%, respectively) (Table 1). We used
a logistic regression model to test the
association between 46C/C and HIV
acquisition using gender and the first
EIGENSTRAT axis as covariates. We
found no association of the46C/C geno-
type with HIV acquisition (odds ratio [OR]
0.864, 95% CI 0.534–1.41, p = 0.555;
without correction for population stratifi-
cation, OR = 1.05, 95% CI 0.685–1.63,
p = 0.809). Assuming an OR of 1.5, as
was reported in He et al., we calculate
that our study has 60% power to detect
an effect of the DARC polymorphism at
the 0.05 level. Our results, however, are
not only not significant, but when correct-
ing for population stratification, they are in
the opposite direction of those reported
by He et al. (OR < 1.0). We used a simple
simulation framework to test the proba-bility of a lower allele frequency in HIV+
samples compared to controls (that is,
an OR < 1, opposite to the direction previ-
ously reported), assuming that theHeet al.
estimate of anOR of 1.5 is correct. Specif-
ically, we simulated random sampling of
471 individuals, assuming a base allele
frequency of 0.70 for the risk genotype,
and compared this with 227 individuals
sampled from a population with a base
allele genotype of 0.60. After repeating
this procedure 1 million times, we found
that the probability that the observed OR
would be below 1 was p < 0.01, indicating
that the observed OR of 0.864 is an
unlikely outcome if the real effect of
the variant is in the same direction and
of similar magnitude to that reported in
He et al.
Although the previous report identified
theDARC46C/C genotype as an impor-
tant risk factor for HIV acquisition andTable 1. Genotypes of the HIV+ and HIV Cohorts at DARC 46T/C
HIV+ Expected HIV+ HIV Expected HIV
46C/C 333 322 157 155
46C/T 113 135 62 65
46T/T 25 14 8 7
Total 471 471 227 227
Percent C/C 70.7% 68.3%
Percent C/T + T/T 29.3% 31.7%
F(C) 0.827 0.828
F(T) 0.173 0.172
HWE P-value 0.073 0.934
Genotype at the DARC 46T/C does not violate HWE in either population. The low p value in the
HIV+ population is caused by an excess of both homozygous states, as opposed to a consistent
overrepresentation of one allele, as would be expected for a true risk allele.Cell Host & Microdisease progression, the work presented
here, corrected for population stratifica-
tion, does not replicate these findings.
Whereas He et al. reported an overrepre-
sentation of the DARC 46C/C genotype
in anHIV+population,weobservedsimilar
allele frequencies in the HIV+ and HIV
populations. It is possible that this result
is indicative of the modest power of our
acquisition study; however, it must be
emphasized that in addition to a lack of
effect on HIV acquisition, a well-powered
analysis of disease course indicates
trends in the opposite direction of those
previously published. The cohort used in
our study offers several advantages. For
the disease progression analyses, our
cohort is larger, includes members from
all three U.S. military services (only one
was evaluated in the previous report),
and includes only subjects with estimated
datesof seroconversion formore accurate
time-to-event analyses. Therefore, while
we cannot rule out the possibility that
DARC 46C/C could be associated with
faster time to death, it does not appear
to be associated with slower progression
to AIDS or with CD4 decline among
African Americans.
Another possible explanation for the
discrepant results relates to population
stratification. Stratification due to popula-
tion substructure can create spurious
associations between alleles and traits
when both differ between subpopulations
(Pritchard et al., 2000; Reich and Gold-
stein, 2001). Of particular concern, the
strengthof thestratificationeffect is known
to increase sharply with the magnitude ofbe 5, May 21, 2009 ª2009 Elsevier Inc. 409
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subpopulations. Thus, theDARC null allele
would be expected to have a particularly
large stratification effect associated with
it in African American populations. He
et al. reported the use of 11 markers to
develop a model to predict ancestry and
to control for the effects of stratification.
It appears that He et al. used the proba-
bility of assignment of individuals to one
of the two population groups (African
American versus European American)
directly as a covariate to control for popu-
lation stratification. In addition to the fact
that 11 markers are insufficient to accu-
rately estimate ancestry and control for
stratification, a model that predicts the
probability of membership in one group
versus another (African American versus
European American) is not the same as a
predictor of the degree of African versus
European ancestry. The latter prediction
is what is required for appropriate control
of stratification. For these reasons, He
et al. did not implement appropriate strati-
fication controls, and it seems likely that
some or all of their association signals
may be due to stratification.
In conclusion, we have found no asso-
ciation between DARC genotype and
progression to AIDS or risk for HIV acqui-
sition. This highlights the importance of
strict control for population stratification
in genetic association studies.
SUPPLEMENTAL DATA
Supplemental Data include one table and three
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